Charles River Seeks Expansion In China For Outsourced Tests
This article was originally published in PharmAsia News
Executive Summary
U.S.-based Charles River Laboratories of the United States says it plans to expand its presence in China and add people and new technologies. James Foster, CEO of the company founded by his father, said his company, which supplies genetically engineered rats and mice for research, needs to increase its own pipeline to meet the demands of drug research and a drug maker need to get products to market more rapidly. Foster said his firm would add new locations in China for outsourcing work and help accelerate that development. (Click here for more
You may also be interested in...
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.